28 March 2019

Contents

Editorial

• 29 March 2019: vol 20 no 4 – second CROI reports

Conference reports

• Conference on Retroviruses and Opportunistic Infections (CROI 2019): second reports

• Maturation inhibitor GSK’232 reduces viral load by –1.5 log at day 10

• Capsid inhibitor GS-6207 shows potential for 3-monthly injections

• First phase 1 results from bNAb PGT121 in HIV positive people

• Dolutegravir/3TC dual ART is as effective at lowest viral load cut-off as triple therapy in GEMINI studies

• Same-day ART is effective in San Francisco Rapid-ART clinic

• Integrase inhibitors and neural tube defects: more data still needed

• Double-dose levonorgestrel implant does not overcome interaction with efavirenz

• Efavirenz and rifampicin together reduce levels of injectable contraception

• Bedaquiline and delamanid safe when given together to treat drug resistant TB

• Isoniazid preventative therapy in HIV positive pregnant women not linked to poor outcomes

Pregnancy

• Dear Doctor letter: Increased risk of treatment failure and increased risk of mother-to-child transmission of HIV infection dues to lower exposure of elvitegravir and cobicistat during the second and third trimesters of pregnancy

PDFs

• 29 March 2019 vol 20 no 4